Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31419989 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL30842608 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL21680243 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL3490337 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL30288493 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL23489619 | 0.82 | CES2 (0.49) | PNMTSLC6A2SLC6A4CES2CES1 | |
| SCHEMBL20833722 | 0.82 | CES2 (0.49) | PNMTSLC6A2SLC6A4CES2CES1 | |
| SCHEMBL7783860 | 0.82 | CES2 (0.49) | PNMTSLC6A2SLC6A4CES2CES1 | |
| SCHEMBL30988818 | 0.82 | CES2 (0.49) | SLC6A2SLC6A4CYP3A4CES2CES1 | |
| SCHEMBL17660052 | 0.82 | CES2 (0.49) | SLC6A2SLC6A4CYP3A4CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | ALI MOHAMMED A | 2010-03-04 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| CN-101203244-A | Compositions of rennin inhibitor and insulin secernent or insulin sensitizer | NOVARTIS AG (CH) | 2008-06-18 | — | — | CN | claimed |
| EP-1907004-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| JP-2007500717-A | — | — | 2007-01-18 | — | — | JP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4516778-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-112601749-B | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-4224224-A | Certain 1-(carbocyclic aryl)-1-halo(or mesyloxy or tosyloxy)-2-(3'-alkoxycarbonylguanidino) ethanes | SYNTEX (U.S.A.) INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4172204-A | Method for preparing 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles and intermediates thereof | SYNTEX (U.S.A.) INC. (US) | 1979-10-23 | — | — | US | disclosed |
| EP-0001500-A1 | 1-Carbocyclic aryl-2-mono or -bis(alkoxycarbonyl) guanidino ethanes, and methods for their preparation and the preparation therefrom of 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles | SYNTEX (U.S.A.) INC. (US) | 1979-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | PNMT 2774/4885SLC6A2 4000/4885SLC6A4 4274/4885 |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, IAPP, ACE | PNMT 2885/4885SLC6A2 296/4885SLC6A4 442/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | PNMT 4389/4885SLC6A2 2541/4885SLC6A4 2731/4885 |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | PNMT 689/4885SLC6A2 1243/4885SLC6A4 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.